Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Creative Commons License

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...Daha Fazla

ANNALS OF NEUROLOGY, cilt.77, sa.3, ss.425-435, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1002/ana.24339
  • Dergi Adı: ANNALS OF NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.425-435
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.